Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

AMAL Therapeutics Enters Clinical Collaboration with Boehringer Ingelheim to Evaluate ATP128 in Combination with BI754091

b3cnewswireMay 05, 2019

Tag: AMAL , boehringer , Ingelheim , ATP128 , BI754091

PharmaSources Customer Service